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tients carrying the ΔYTT deletion, T78K and W101C missense mutations in caveolin-3. iPSCs displayed normal
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and ability to differentiate in vitro into the three germ layers. These lines thus represent a human cellular
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Unique stem cell lines
identiﬁer
EURACi001-A
EURACi002-A
EURACi003-A
Method of
reprogramming
Electroporation of episomal vectors (pCXLE
hOCT3/4-shp53-F, pCXLE-hSK, and pCXLE-hUL)
Multiline rationale Non-isogenic cell lines obtained from patients with mu-
tations in the same gene (CAV3)
Gene modiﬁcation NO
Type of modiﬁcation Spontaneous mutations
Associated disease Caveolinopathies
Gene/locus Heterozygous CAV3 c.Δ184–192 (EURACi001-A)
Heterozygous CAV3 c.303 TGG N TGC (EURACi002-A)
Heterozygous CAV3 c.233 ACG N AAG (EURACi003-A)
Method of modiﬁcation N/A
Name of transgene or
resistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock
date
January 2016 (EURACi001-A)
September 2016 (EURACi002-A)
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(continued)
Unique stem cell lines
identiﬁer
EURACi001-A
EURACi002-A
EURACi003-A
May 2016 (EURACi003-A)
Cell line
repository/bank
N/A
Ethical approval Peripheral blood was collected from patients after
signing the informed consent provided by Cell Line and
DNA Biobank from Patients Affected by Genetic Diseases,
member of the Telethon Network of Genetic Biobanks,
Istituto G. Gaslini, Genoa, Italy. The generation and use of
iPSCs was reviewed and approved by Ethical Committee
at Universita’ degli Studi di Milano (03.06.15, number
29/15).
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The established iPSC lines (EURACi001-A, EURACi002-A,
EURACi003-A) provide a resource to generate in vitro human
cardiomyocytes and myoblast/myotubes in order to understand the
molecular and functional mechanisms leading to altered cellular excit-
ability typical of these pathological CAV3 mutations and to evaluate a
pharmacological approach to eventually correct such alterations.
Resource details
The term caveolinopathies refers to a group of primary myopathies
resulting from alteration of the proteins named caveolin-3, the main
constituent of muscle caveolae. These genetic disorders are mainly
inherited through an autosomal dominant pattern. The plasma mem-
brane of cardiomyocytes is rich in caveolae and caveolins play multiple
roles in the physiology of cardiovascular system (Panneerselvam et al.,
2012). Beyond its role in maintaining the structural integrity of caveo-
lae, caveolin-3 is known to interact with several ion channels in the
heart, modifying their functional properties and expression levels
(Barbuti et al., 2012; Campostrini et al., 2017). In order to elucidate in
detail the role of CAV3mutations in skeletalmuscle and cardiac diseases,
the availability of large quantities of human skeletal muscle and cardiac
myocytes is a major requirement. Since iPSC can be differentiated in
both these cell types, they provide an unlimited source of human cells
otherwise unavailable.We generated iPSCs from three patients carrying
different heterozygous mutations in CAV3 genes (Table 1): one patient
who carries a deletion c.Δ184-192 (ΔYTT), one with c.303 TGG N TGC
(W101C) mutation and another patient showing c.233 ACG N AAG
(T78K) mutation. At least four iPSC clones were generated from each
patient and the iPSC clones (EURACi001-A, EURACi002-A, EURACi003-
A) reported in this work were randomly selected and successfully char-
acterized. Speciﬁcally, iPSCs were obtained from peripheral blood
mononuclear cells (PBMCs) using electroporation of episomal plasmids
carrying OCT3/4, SOX2, KLF4, and L-MYC (Meraviglia et al., 2015). iPSC
colonies showed a typical human embryonic-stem cell morphology
and were positive for alkaline phosphatase staining (Supplementary
Fig. 1A). qRT-PCR analysis revealed that all iPSC lines expressed endog-
enous pluripotency genes (SOX2, OCT3, NANOG) at higher levels com-
pared to their PBMCs counterpart (Supplementary Fig. 1B).
Immunoﬂuorescence analysis showed the expression of theTable 1
Summary of lines.
iPSC line names Abbreviation in ﬁgures Gender Age Ethnici
EURACi001-A EURACi001-A Female 36 Caucas
EURACi002-A EURACi002-A Female 22 Caucas
EURACi003-A EURACi003-A Female 43 Caucaspluripotency markers OCT4, SOX2 at nuclear level and SSEA4, TRA-1-
60 as surface proteins (Fig. 1A). Flow cytometry allowed to quantify
the percentage of cell positive for SSEA4 (≥97.8%) and SOX2 (≥79.8)
in all the three iPSC lines (Fig. 1B). The ability of iPSC lines to differenti-
ate into cells of the three germ layers following embryoid body (EB) for-
mation was assessed by qPCR on endodermal (SOX7 and AFP in green),
mesodermal (CD31, ACTA2, SCL and CDH5 in red) and ectodermal
(KTR14, NCAM1, TH and GABRR2 in blue) genes (Fig. 1C). Further-
more, direct cardiomyogenic differentiation of all iPSC lines led to
the formation of cardiomyocytes, as indicated by immunoﬂuorescence
staining of speciﬁc cardiac marker (α-Actinin), which displayed a clear
sarcomeric pattern (Fig. 1D). Also, cytogenetic analysis was performed
on all iPSC lines, showing a normal karyotype (Supplementary Fig. 1C)
and genomic DNA sequencing conﬁrmed the presence of all the three
mutations in CAV3 gene (Supplementary Fig. 1D). Then, STR analysis
indicated that iPSCs and their PBMC counterparts yielded a match
≥98%, conﬁrming that they are correctly derived from the donor
(Table 2, data not shown). Finally, PCR results indicated that all the
iPSC lines were negative for mycoplasma contamination (Supplemen-
tary Fig. 1E).1. Materials and methods
1.1. Cell culture and reprogramming
PBMCs obtained from venous peripheral blood were ampliﬁed in
suspension as previously described (Meraviglia et al., 2015). 5 × 106
PBMCswere reprogrammed by electroporation of 1 μg of each episomal
vector (pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, and pCXLE-hUL from
Addgene) using Neon System (Thermo Fisher Scientiﬁc) following the
program: 1650 V, 10 ms, 3 pulses. Three days after electroporation,
transfected PBMCs were plated on a feeder layer of irradiated mouse
embryonic ﬁbroblasts (MEFs) and cultured in iPSC medium containing
knockout DMEM, 20% KO-Serum Replacement, 1 mM NEAAs, 1% Peni-
cillin/Streptomycin, 1% L-Glutamine, 0.1 mM β-mercaptoethanol (all
from Thermo Fisher Scientiﬁc) and 10 ng/ml bFGF (Merck-Millipore)
(Meraviglia et al., 2015). IPSCs maintained on MEFs were expanded by
enzymatic dissociation using 1 mg/ml Collagenase IV (Thermo Fisher
Scientiﬁc). IPSCs adapted to feeder-free condition were cultured in
TeSR-E8 medium (Stem Cell Technologies) on Matrigel matrix
(Corning) and propagated using PBS-EDTA 0.5 mM.1.2. iPSC differentiation
For differentiation into the three germ layer, iPSCs onMEFswere de-
tached and grown in ultra-low attachment plates for 7 days to form EBs
in KO-DMEM (Thermo Fisher Scientiﬁc) with 20% FBS Deﬁned
(Hyclone), 1 mM NEAAs, 1% Penicillin/Streptomycin, 1% L-Glutamine,
0.1 mM β-mercaptoethanol (all from Thermo Fisher Scientiﬁc). EBs
were then plated onto 0.1% gelatin-coated dishes for further
10–15 days of differentiation.
Cardiomyogenic differentiation was performed on iPSC cultured in
feeder free condition, plating 20,000 cells/cm2 on 24-well plate coated
withMatrigel and using PSC Cardiomyocyte Differentiation Kit (Thermo
Fisher Scientiﬁc), according to manufacturer's instructions.ty Genotype of locus Disease
ian Het c.Δ184-192 Limb-girdle muscular dystrophy (LGMD-1C)
ian Het c.303 TGG N TGC Isolated Hyper-CKEmia
ian Het c.233 ACG N AAG Hyper-CKemia and Rippling Muscle Disease
Fig. 1. Generation and characterization of three iPSC lines EURACi001-A, EURACi002-A and EURACi003-A. (A) Immunoﬂuorescence staining for pluripotencymarkers SSEA4, OCT4, SOX2
and TRA-1-60; scale bar 100 μm. (B) Flow citometry analysis of pluripotencymarkers SSEA4 ad SOX2. (C) Gene expression analysis of three germ layermarkers after iPSCdifferentiation via
embryoid body formation. (D) Representative immunoﬂuorescence images for sarcomeric protein α-Actinin after direct cardiomyogenic differentiation; scale bar 50 μm.
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Pluripotency markers were detected using Pluripotent Stem Cell 4-
Marker Immunocytochemistry Kit (Thermo Fisher Scientiﬁc) as indicat-
ed by manufacturer's instruction (Table 3).
After 35 days of differentiation, cardiomyocyteswere ﬁxed in PFA 4%
for 10 min at room temperature. Blocking of unspeciﬁc sites was
achieved by incubation with 3% donkey serum in the presence of 0.3%
Triton-X100 for 1 h at room temperature. Primary antibodies were in-
cubated overnight at 4 °C, while secondary antibodies were incubated
45 min at room temperature (Table 3). Nuclei were stained with DAPI
(Sigma-Aldrich).
1.4. Flow cytometry
Flow Cytometry analysis was performed usingMulti-Color Flow Cy-
tometry Kit (R&D System) following manufacturer's instruction. Sam-
ples were analyzed using FACSAriaII™ ﬂow cytometry (BD Bioscience).
1.5. qRT-PCR
Total RNA from PBMCs, iPSCs and EBs was extracted using TRIzol®
Reagent and 1 μg of RNA was reverse transcribed using SuperScript
VILO cDNA Synthesis Kit following manufacturer's instruction (allfrom Thermo Fisher Scientiﬁc). cDNA was ampliﬁed using All-in-One
SYBR®Green qPCRMix (GeneCopoeia) on CFX96 Real-Time PCR Detec-
tion System (BioRad). Primers sequences were reported in Table 3.1.6. Karyotiping
Cytogenetic Q-banding analysis was performed as previously de-
scribed (Meraviglia et al., 2015).1.7. Sequencing and STR analysis
Genomic DNA from both iPSCs and corresponding PBMCs was sent
to Euroﬁns Genomics (Germany) for analysis, according to ANSI/ATCC
standard ASN-0002 (Table 2). In particular, 21 independent loci were
investigated by PCR-single-locus-technology (Promega, PowerPlex 21
PCR Kit).1.8. Mycoplasma test
The mycoplasma contamination test was carried out by PCR using
primers able to recognize most of the Mycoplasma species (Table 3).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2017.12.012.
Table 2
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Light miscroscopy Normal morphology and alkaline phosphatase positivity Supplementary Fig. 1A
Phenotype Immunocytochemisty Expression of pluripotency markers: SSEA4, OCT4, TRA-1-60,
SOX2
Fig. 1A
Flow cytometry EURACi001-A positivity to: Fig. 1B
SSEA4 99.9 ± 0.05%;
SOX2 = 96.4 ± 0.94%
EURACi002-A positivity to:
SSEA4 99.4% ± 0.19%;
SOX2 79.8% ± 7.56%
EURACi003-A positivity to:
SSEA4 97.8% ± 2.07%;
SOX2 88.0% ± 7.06%
Genotype Karyotype (Q-banding)
Resolution: 300–400 bands
Normal karyotype: 46, XX for all the three iPSC lines Supplementary Fig. 1C
Identity Microsatellite PCR (mPCR) Not performed
STR analysis 21 markers tested: Amelogenin (for gender identiﬁcation),
D3S1358, D1S1656, D6S1043, D13S317, Penta E, D16S539,
D18S51, D2S1338, CSF1PO, Penta D, TH01, vWA, D21S11,
D7S820, D5S818, TPOX, D8S1179, D12S391, D19S433 and FGA
(Promega PowerPlex 21 Kit) with match ≥98%
Submitted in archive with journal
Mutation analysis
(IF APPLICABLE)
Sequencing c.Δ184–192 (EURACi001-A) Supplementary Fig. 1D
c.303 TGG N TGC (EURACi002-A)
c.233 ACG N AAG (EURACi003-A)
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by PCR: Negative Supplementary Fig. 1E
Differentiation potential Embryoid body formation AND Direct
differentiation
Expression of genes of the three germ layers in embryoid
bodies (SOX7 and AFP for endoderm; CD31, ACTA2, SCL and
CDH5 for mesoderm; KRT14, NCAM1, TH and GABBR2 for
ectoderm) and directed differentiation into cardiomyocytes
Fig. 1C (gene expression analysis)
and Fig. 1D
(immunocytochemistry for cardiac
marker)
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers (immunocytochemistry) Rabbit anti-OCT4 1:100 Thermo Fisher Scientiﬁc Cat# A24867, RRID:AB_2650999
Pluripotency markers (immunocytochemistry) Mouse anti-SSEA4 (IgG3) 1:100 Thermo Fisher Scientiﬁc Cat# A24866, RRID:AB_2651001
Pluripotency markers (immunocytochemistry) Rat anti-SOX2 1:100 Thermo Fisher Scientiﬁc Cat# A24759, RRID:AB_2651000
Pluripotency markers (immunocytochemistry) Mouse anti-TRA-1-60 (IgM) 1:100 Thermo Fisher Scientiﬁc Cat# A24868, RRID:AB_2651002
Secondary antibodies (immunocytochemistry) Alexa Fluor® 555 Donkey Anti-Rabbit 1:250 Thermo Fisher Scientiﬁc Cat# A24869, RRID:AB_2651006
Secondary antibodies (immunocytochemistry) Alexa Fluor® 488 Goat Anti-Mouse IgG3 1:250 Thermo Fisher Scientiﬁc Cat# A24877, RRID:AB_2651008
Secondary antibodies (immunocytochemistry) Alexa Fluor® 488 Donkey Anti-Rat 1:250 Thermo Fisher Scientiﬁc Cat# A24876, RRID:AB_2651007
Secondary antibodies (immunocytochemistry) Alexa Fluor® 555 Goat Anti-Mouse IgM 1:250 Thermo Fisher Scientiﬁc Cat# A24871, RRID:AB_2651009
Pluripotency markers (ﬂow cytometry) PE-SOX2 Mouse IgG2A 1:20 R&D System Cat# IC2018P, RRID:AB_357273
Pluripotency markers (ﬂow cytometry) CFS-SSEA-4 Mouse IgG3 1:20 R&D System Cat# FAB1435F, RRID:AB_952015
Pluripotency markers (ﬂow cytometry) PE Isotype control- mouse IgG2A 1:20 R&D System Cat# IC003P, RRID:AB_357245
Pluripotency markers (ﬂow cytometry) CFS Isotype control- Mouse IgG3 1:20 R&D System Cat# IC007F, RRID:AB_952037
Cardiomyocyte markers (immunocytochemistry) Mouse anti-Sarcomeric actin 1:400 Sigma Aldrich Cat# A7732, RRID:AB_2221571
Secondary antibodies (immunocytochemistry) Alexa Fluor® 488 Goat Anti-Mouse IgG 1:600 Thermo Fisher Scientiﬁc Cat# A21202, RRID:AB_141607
Primers
Target Forward/reverse primer (5′–3′)
Pluripotency Markers (qRT-PCR) SOX2 GGGAAATGGGAGGGGTGCAAAAGAGG/TTGCGTGAGTGTGGATGGGATTGGTG
Pluripotency Markers (qRT-PCR) OCT4 GACAGGGGGAGGGGAGGAGCTAGG/CTTCCCTCCAACCAGTTGCCCCAAAC
Pluripotency Markers (qRT-PCR) NANOG TGCAAGAACTCTCCAACATCCT/ATTGCTATTCTTCGGCCAGTT
Three germ layer markers (endoderm) (qRT-PCR) SOX7 TGAACGCCTTCATGGTTTG/AGCGCCTTCCACGACTTT
Three germ layer markers (endoderm) (qRT-PCR) AFP GTGCCAAGCTCAGGGTGTAG/CAGCCTCAAGTTGTTCCTCTG
Three germ layer markers (mesoderm) (qRT-PCR) CD31 ATGCCGTGGAAAGCAGATAC/CTGTTCTTCTCGGAACATGGA
Three germ layer markers (mesoderm) (qRT-PCR) ACTA2 GTGATCACCATCGGAAATGAA/TCATGATGCTGTTGTAGGTGGT
Three germ layer markers (mesoderm) (qRT-PCR) SCL CCAACAATCGAGTGAAGAGGA/CCGGCTGTTGGTGAAGATAC
Three germ layer markers (mesoderm) (qRT-PCR) CDH5 GAGCATCCAGGCAGTGGTAG/CAGGAAGATGAGCAGGGTGA
Three germ layer markers (ectoderm) (qRT-PCR) KRT14 CACCTCTCCTCCTCCCAGTT/ATGACCTTGGTGCGGATTT
Three germ layer markers (neuro-ectoderm) (qRT-PCR) NCAM1 CAGATGGGAGAGGATGGAAA/CAGACGGGAGCCTGATCTCT
Three germ layer markers (neuro-ectoderm) (qRT-PCR) TH TGTACTGGTTCACGGTGGAGT/TCTCAGGCTCCTCAGACAGG
Three germ layer markers (neuro-ectoderm) (qRT-PCR) GABRR2 CTGTGCCTGCCAGAGTTTCA/ACGGCCTTGACGTAGGAGA
House-Keeping Gene (qRT-PCR) GAPDH CCACCCATGGCAAATTCC/TCGCTCCTGGAAGATGGTG
Mutation analysis (sequencing) CAV3 TGTGGGCACCTACAGCTTTGAC/CACCTGGCTTTAGACCTCCTTC
Mycoplasma detection TGCACCATCTGTCACTCTGTTAACCTC/ACTCCTACGGGAGGCAGCAGTA
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